Abliva Overview
- Founded
- 2000

- Status
- Public
- Employees
- 8

- Stock Symbol
- ABLI

- Investments
- 2
- Share Price
- $0.04
- (As of Tuesday Closing)
Abliva General Information
Description
Abliva AB is a Swedish company which is active in pharmaceutical development. It develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare and often very severe diseases occur when the cell's energy provider, the mitochondria, do not function properly. The portfolio includes projects at different stages and ranges from early discovery phase to clinical phase.
Contact Information
- Medicon Village
- 223 81 Lund
- Sweden
Abliva Stock Performance
(As of Tuesday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$0.04 | $0.04 | $0.04 - $0.09 | $15.6M | 403M | 488K | -$0.04 |
Abliva Financials Summary
In Thousands, USD |
TTM 31-Dec-2021 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
---|---|---|---|---|
EV | 19,426 | 19,426 | 19,478 | 18,505 |
Revenue | 18 | 18 | 23 | 14 |
EBITDA | (14,069) | (14,069) | (6,229) | (7,889) |
Net Income | (14,380) | (14,380) | (6,506) | (8,140) |
Total Assets | 6,510 | 6,510 | 12,063 | 15,882 |
Total Debt | 0 | 0 | 0 | 0 |
Abliva Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
This information is available in the PitchBook Platform. To explore Abliva‘s full profile, request access.
Request a free trialAbliva Comparisons
Industry
00000
000000 0
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialAbliva Competitors (32)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Orexo | Formerly VC-backed | Uppsala, Sweden | 000 | 000.00 | 00000000 | 000.00 |
000000 00000000000 | Formerly VC-backed | San Diego, CA | 000 | 00000 | 000000&0 | |
00000000 | Formerly VC-backed | Jersey City, NJ | 00 | 00000 | 000000000 | 00000 |
00000000 | Formerly VC-backed | Durham, NC | 00 | 00000 | 000000 - 000 | 00000 |
0000000 0000000000 | Corporation | Framingham, MA | 0 | 000.00 | 000000000 | 000.00 |
Abliva Patents
Abliva Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
CA-3043131-A1 | Use of sanglifehrin macrocyclic analogues as anticancer compounds | Pending | 18-Nov-2016 | 000000000 | |
EP-3541388-A1 | Use of sanglifehrin macrocyclic analogues as anticancer compounds | Withdrawn | 18-Nov-2016 | 000000000 | |
US-20190328734-A1 | Use of sanglifehrin macrocyclic analogues as anticancer compounds | Granted | 18-Nov-2016 | 000000000 | |
US-10857150-B2 | Use of sanglifehrin macrocyclic analogues as anticancer compounds | Active | 18-Nov-2016 | 0000000000 | |
JP-2019535726-A | Use of sanglifehrin macrocyclic analogues as anticancer compounds | Pending | 18-Nov-2016 | A61K31/50 |
Abliva Executive Team (8)
Abliva Board Members (2)
Name | Representing | Role | Since |
---|---|---|---|
David Laskow-Pooley | Self | Chairman & Board Member | 000 0000 |
Abliva Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialAbliva Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
This information is available in the PitchBook Platform. To explore Abliva‘s full profile, request access.
Request a free trialAbliva Investments & Acquisitions (2)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
000000000 000 | 15-Aug-2016 | 00000 0000 | 00.000 | Drug Discovery | 0000 0000 |
Biotica Technology | 11-Mar-2013 | Merger/Acquisition | Biotechnology |